Gadolinium concentration dependent signal enhancement profiles using routine clinical sequences with gadopiclenol, gadoterate, gadobutrol, and gadoxetate at 1.5, 3 and 7 Tesla
Open Access
- 16 July 2025
- journal article
- Published by Elsevier in European Journal of Radiology
- Vol. 191, 112322
Abstract
No abstract availableKeywords
Funding Information
- Universitätsklinik Balgrist
- Siemens
This publication has 22 references indexed in Scilit:
- Contrast‐enhanced MRI for breast cancer screeningJournal of Magnetic Resonance Imaging, 2019
- T1 Relaxivities of Gadolinium-Based Magnetic Resonance Contrast Agents in Human Whole Blood at 1.5, 3, and 7 TInvestigative Radiology, 2015
- The Protein and Contrast Agent–Specific Influence of Pathological Plasma-Protein Concentration Levels on Contrast-Enhanced Magnetic Resonance ImagingInvestigative Radiology, 2014
- MRI contrast agents: Basic chemistry and safetyJournal of Magnetic Resonance Imaging, 2012
- User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliabilityNeuroImage, 2006
- Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass SpectroscopyInvestigative Radiology, 2006
- Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 TeslaInvestigative Radiology, 2006
- Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field StrengthsInvestigative Radiology, 2005
- Rapid calculation of T1 using variable flip angle gradient refocused imagingMagnetic Resonance Imaging, 1987
- Optimal determination of relaxation times of fourier transform nuclear magnetic resonance. Determination of spin-lattice relaxation times in chemically polarized speciesThe Journal of Physical Chemistry, 1974